28th Apr 2006 15:38
Aortech International PLC28 April 2006 For Immediate Release 28 April 2006 AorTech International plc ("AorTech" or the "Company") AorTech International (AIM.AOR), is pleased to announce that Dr. Carlos Ruiz,MD, PhD of the Lennox Hill Heart and Vascular Institute of New York made apresentation today at the opening of the Transcatheter Valve Symposium (TVS-3),in California, USA, regarding the performance and advantages of the AorTechM-95-C polymer tri-leaflet heart valve. Dr Ruiz is a Director of the Trans-Cather Valve Symposium and a member of itsBoard. He has no financial interest in or any commercial collaboration withAorTech. AorTech's polymer heart valve, the M-95-C was developed by AorTech Internationaland is manufactured using its proprietary biostable material Elast-Eon(TM).AorTech received notification on March 26, 2006 that its patent for this heartvalve, # GB2407146 had been granted in the UK. Patents in other regions arepending. Frank Maguire, AorTech CEO, commented: "We are delighted to have attracted the interest and support of someone of Dr.Ruiz's stature to make this presentation to his colleagues at this high-profilemeeting. We believe that the M-95-C valve will ultimately be adopted and play asignificant role as a next-generation surgical valve because it combines thebest features of both tissue and mechanical valves and as a percutaneous valvebecause of its ability to be compressed into a very small size for catheterdelivery to the heart." Additional information about the Transcatheter Valve Symposium and AorTech canbe found at www.tvsymposium.com and www.aortech.com For further information please contact: AorTech International plcFrank Maguire, Chief Executive Tel: + 1 801 201 4336 Buchanan Communications Tel: + 44 20 7466 5000Rebecca Skye Dietrich / Ben Willey About AorTech AorTech International plc, is an AIM (Alternative Investment Market), Londonlisted company which wholly owns AorTech Biomaterials based in Melbourne,Australia. AorTech Biomaterials was formed in July 1997 to commercialise a range of medicalgrade polyurethanes for medical implants developed by the CommonwealthScientific and Industrial Research Organisation (CSIRO). This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
AOR.L